Kimia Biosciences Ltd (KIMIABL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Kimia Biosciences Ltd on NSE and BSE, with an AI summary of each filing.
Kimia Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve to consider and approve, ....
Intimation · 13 Nov 2026, 5:30 am
Kimia Biosciences Schedules Board Meeting to Approve Q2 and H1 FY27 Results Kimia Biosciences Limited has scheduled a Board of Directors meeting for 13th Nov'26 to consider and approve the standalone un-audited financial results for the second quarter and half year ended 30th Sep'26. In compliance with SEBI insider trading regulations, the trading window for dealing in company equity shares by designated persons and their immediate relatives has been closed effective 1st Oct'26 and will remain closed until 48 hours post-declaration of the financial results.
Intimation under regulation 30 of LODR Regulation - Change in Management pursuant to approval of members at 33rd Annual General Meeting of the Company.
Change in Management · 30 Sept 2026, 4:56 am
Declaration of Results of Remote E voting and Evoting at AGM held on 28.09.2026 along with Scruitiniser Report provided by Maya Sharma and Associates Company secretaries under regulation ....
Annual General Meeting · 30 Sept 2026, 4:15 am
Submission of proceedings of the 33rd Annual General Meeting pursuant to regulations 30 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015
Annual General Meeting · 28 Sept 2026, 9:35 pm
Thirty Third Annual Report for the Financial Year 2025-2026 of Kimia Biosciences Limited
Others (Uncategorized) · 05 Sept 2026, 4:28 am
Intimation of Cut off Date/ Record Date, E-Voting and AGM date for the 33rd Annual General Meeting
Others · 05 Sept 2026, 12:54 am
Intimation of 33rd Annual General Meeting of the Company proposed to be held on September 28, 2026 at 03:00 P.M. through Video Conferencing/ Other Audio Visual Means.
Annual General Meeting · 04 Sept 2026, 9:56 pm
Outcome of the Meeting of the Board of Directors held on September 03, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Others (Uncategorized) · 04 Sept 2026, 12:17 am
Kimia Biosciences Approves Increased Borrowing Limits and Key Board Appointments On 3rd Sep'26, Kimia Biosciences' board approved resolutions seeking shareholder approval to increase corporate borrowing, investment, and lending limits under the Companies Act, signaling potential capital expansion. The board authorized creating mortgages on company assets to secure future borrowings. Leadership changes include re-appointing founder Sameer Goel as a Director and appointing Amulya Kumar Nayak as Non-Executive Director, alongside two new Independent Directors for five-year terms. These strategic proposals will be presented for approval at the upcoming 33rd AGM scheduled for 28th Sep'26.
Approval of unaudited financial result (Standalone) for quarter ended june 30, 2026.
Financial Result · 10 Aug 2026, 10:42 pm
Kimia Biosciences Q1 FY27 PAT Declines 41% YoY Amid Lower Revenue Kimia Biosciences reported a 41.1% YoY decline in Profit After Tax to ₹35.58 lakhs for Q1 FY27, down from ₹60.40 lakhs. Revenue from Operations fell 12.1% YoY to ₹2,072.25 lakhs. On a QoQ basis, PAT was flat while revenue decreased by 23.8%. Total expenses contracted by 14.4% YoY to ₹2,031.33 lakhs, primarily driven by lower material costs and a favourable change in inventories. Basic EPS for the quarter stood at ₹0.08, compared to ₹0.13 in the prior-year period.
Pursuant to Regulation 33 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have enclosed herewith: 1. Unaudited ....
Outcome · 10 Aug 2026, 10:22 pm
Kimia Biosciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 2,072 (-12.1% YoY | -23.8% QoQ) ■ EBITDA: 235 (-7.1% YoY | -11.9% QoQ) ■ EBITDA Margin (%): 11.3 (+61 bps YoY | +153 bps QoQ) ■ PAT: 35.6 (-41.1% YoY | -0.5% QoQ) ■ EPS (INR): 0.08 (-38.5% YoY | -42.9% QoQ)
Kimia Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Un-Audited Financial Results ....
Intimation · 10 Aug 2026, 5:30 am
Kimia Biosciences Board Meeting to Approve Q1 FY27 Results on 10th Aug'26 Kimia Biosciences Limited has scheduled a Board of Directors meeting for 10th Aug'26 to consider and approve the unaudited standalone financial results for the first quarter ending 30th Jun'26. In compliance with insider trading regulations, the trading window for designated persons has been closed from 1st Jul'26 and will remain closed until 48 hours after the results are declared to the stock exchange. This meeting is crucial for assessing the company's Q1 performance.
Change in Management, appointment of Cost Auditor, Internal Auditor, Secretarial Auditor and Discountinuance/ Cessation of Secretarial Auditor
Change in Management · 02 Aug 2026, 4:47 am
Kimia Biosciences Announces Key Auditor Appointments and Changes Kimia Biosciences' Board, in its meeting on 1st Aug'26, approved key auditor appointments. M/s Mahesh Singh & Co. was appointed Cost Auditor for FY27. M/s Chaudhry & Associates was named Internal Auditor for FY27. M/s M & Co. was discontinued as Secretarial Auditor, effective 1st Aug'26, and replaced by M/s Maya Sharma and Associates for FY26 and FY27. The changes are part of a routine board-level decision-making process concerning corporate governance and compliance roles.
Outcome of the Meeting of the Board of Directors held on August 1, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Appointment ....
Others (Uncategorized) · 02 Aug 2026, 4:43 am
Kimia Biosciences Announces Key Auditor Appointments and Changes Kimia Biosciences' Board, on 01 Aug'26, appointed new auditors. M/s Mahesh Singh & Co. were named Cost Auditor for FY27. M/s Chaudhry & Associates were appointed as Internal Auditor for FY27. Concurrently, the Board discontinued M/s M & Co. as Secretarial Auditor effective 01 Aug'26, appointing M/s Maya Sharma and Associates in their place for FY26 and FY27. These changes reflect a significant overhaul of the company's key audit functions, impacting governance and compliance oversight for the upcoming financial years.
Approval of Audited standalone Financial results alongwith Audited Report thereon for financial year 2025-26
Financial Result · 29 May 2026, 10:57 pm
Kimia Biosciences Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 2,720 (-28.9% YoY | -9.6% QoQ) ■ EBITDA: 267 (-67.4% YoY | -59.3% QoQ) ■ EBITDA Margin (%): 9.8 (-1159 bps YoY | -1198 bps QoQ) ■ PAT: 139 (-68.0% YoY | Loss to Profit QoQ) ■ EPS (INR): 0.15 (-65.1% YoY | -87.0% QoQ)
Kimia Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the Audited Financial Results ....
Intimation · 29 May 2026, 5:30 am
Kimia Biosciences Board to Approve Q4 & FY26 Results on 29th May'26 Kimia Biosciences Ltd. has scheduled a Board of Directors meeting on 29th May'26. The agenda includes the consideration and approval of the Audited Standalone Financial Results for the fourth quarter and financial year ended 31st Mar'26, along with the corresponding Audit Report. The trading window, closed since 1st Apr'26, will reopen 48 hours after the results are declared.
Appointment of Mr. Mani Jain as CFO & KMP w.e.f. 27.04.2026
Change in Management · 28 Apr 2026, 1:36 am
Kimia Biosciences Appoints New Chief Financial Officer Kimia Biosciences Limited has appointed Mr. Mani Jain as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective 27 Apr'26. Mr. Jain is a Chartered Accountant with over 28 years of experience in finance, accounts, treasury, taxation, audits, and strategic financial management. He has previously held senior leadership positions and has extensive experience in fundraising, project finance, and business planning. Mr. Jain is not related to any director and is not debarred by any authority from holding office.
Outcome of Board Meeting held on 18 April 2026 under regulation 30 of Sebi(Lodr) Regulations 2015 - Change in Management
Change in Management · 19 Apr 2026, 1:01 am
Kimia Biosciences Announces Board and Committee Changes Kimia Biosciences announced key management changes from its board meeting on 18th Apr'26. Ms. Richa Gupta ceased to be an Independent Director effective 14th Apr'26 upon completing her maximum ten-year tenure. The company appointed Mr. Amulya Kumar Nayak as an Additional Non-Executive Director from 18th Apr'26. Additionally, the board modified the terms of MD Mr. Sameer Goel's re-appointment, making him liable to retire by rotation. Consequent to these changes, the Board Committees, including the Nomination & Remuneration Committee, were reconstituted.
We would like to inform you that company is in compliance with provision of Reg 30 of SEBI(LODR) Regulations 2015 and has been promptly intimating to exchange all events, information and ....
Others (Uncategorized) · 14 Apr 2026, 8:21 pm
Kimia Biosciences Clarifies Share Price Movement to BSE Kimia Biosciences, in a response to the BSE dated 14 Apr'26, clarified that its recent share price movement is purely market-driven. The company affirmed it has no control over the price action. Management stated there is no undisclosed price-sensitive information or any pending corporate action that could be influencing the stock. The company confirmed it is fully compliant with SEBI (LODR) Regulations, 2015 and has promptly disclosed all material information that could impact its operations or performance.
The Exchange has sought clarification from Kimia Biosciences Ltd on April 13, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 14 Apr 2026, 12:57 am
Intimation of change of management under regulation 30 of SEBI LODR 2015
Change in Management · 04 Apr 2026, 10:38 pm
Kimia Biosciences Announces Board and KMP Changes Kimia Biosciences announced significant board and key managerial personnel (KMP) changes effective 04 Apr'26. Mr. Avinash Prabhat and Ms. Reema Goyal were appointed as Additional Non-Executive Independent Directors for five-year terms. Concurrently, Mr. Jagdeep Dhawan ceased to be an Independent Director effective 28 Mar'26 upon tenure completion. The company also noted the resignation of Ms. Pallavi Garg as Company Secretary (CS) on 03 Apr'26 and appointed Mr. Abhishek Kumar Pandey as the new CS & Compliance Officer from 04 Apr'26.
Intimation of Resignation of Pallavi Garg as Company Secretary and Compliance officer of the company w.e.f. 03.04.2026.
Change in Management · 04 Apr 2026, 3:14 am
Kimia Biosciences CS & Compliance Officer Resigns Pallavi Garg has resigned from her position as Company Secretary & Compliance Officer and Key Managerial Personnel at Kimia Biosciences Limited, citing personal reasons. The resignation is effective from the close of business hours on 03rd Apr'26. The company's Board of Directors will formally consider the resignation at its next meeting. This change in key management personnel is a notable governance event for the company.
Resignation of Additional Director(in the category of Executive Director)
Change in Management · 20 Feb 2026, 3:28 am
Kimia Biosciences Announces Resignation of Executive Director Kaku Reddy Kimia Biosciences announced that Mr. Kaku Vijaya Shekhar Reddy (DIN: 00800172) has resigned from his position as Additional Director (Executive Director) for personal reasons. His resignation was tendered on 18 Feb'26 and accepted by the company, effective from the close of business hours on 19 Feb'26. Mr. Reddy, who also held the role of Director Technical, had been with the company since 5 Dec'25, serving for a very brief tenure of just over two months.
Intimation under Regulation 30 of SEBI(Listing Obligations and Disclosures Requirement)Regulation 2015-modification in Postal Ballot notice
Others (Uncategorized) · 16 Feb 2026, 10:51 pm
Kimia Biosciences Modifies Postal Ballot, Defers Director Regularisation Kimia Biosciences announced on 16th Feb'26 a modification to its upcoming Postal Ballot notice. The revised agenda will now solely contain the proposal for the re-appointment of Mr. Sameer Goel as Managing Director for a five-year term. The agenda item concerning the regularisation of Mr. Kaku Vijaya Shekhar Reddy as Whole-time Director has been withdrawn and put on hold due to internal considerations. The company stated this matter would be considered later and the revised notice will be circulated to shareholders.
Results for the financial for the quarter and nine months ended on 31st December 2025
Financial Result · 14 Feb 2026, 8:17 pm
Kimia Biosciences Q3FY26 PAT Rises Sharply QoQ; Board Approves Management Re-appointments Kimia Biosciences reported a Q3FY26 standalone PAT of ₹544.15 lakhs, a significant increase from ₹101.51 lakhs QoQ, but up just 19% from ₹457.02 lakhs YoY. Revenue from operations for the quarter stood at ₹3,010.06 lakhs, a 11.5% QoQ decline. For the nine months ended 31 Dec'25, PAT was ₹706.06 lakhs, down 7.3% YoY. The board approved the unaudited results and the re-appointment of Sameer Goel as Managing Director for five years, subject to shareholder approval via postal ballot.
Board Meeting outcome
Outcome · 14 Feb 2026, 8:10 pm
KIMIA BIOSCIENCES LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakh) ■ Revenue: 3010 (+0.0% YoY | -11.5% QoQ) ■ EBITDA: 655 (+31.2% YoY | +160.1% QoQ) ■ EBITDA Margin (%): 21.8 (+518 bps YoY | +1436 bps QoQ) ■ PAT: 544 (+19.1% YoY | +436.1% QoQ) ■ EPS (INR): 1.15 (+18.6% YoY | +447.6% QoQ)